课题基金 / 基金详情

Characterization of Epstein-Barr virus monoclonal antibodies as tools for diagnosing and prevention of EBV infection in transplant settings

Characterization of Epstein-Barr virus monoclonal antibodies as tools for diagnosing and prevention of EBV infection in transplant settings
EB 病毒单克隆抗体作为移植环境中诊断和预防 EBV 感染工具的表征
批准号:
9797160
负责人:
Javier Gordon Ogembo
金额:
$6.65万
依托单位国家:
美国
项目类别:
财政年份:
2018
资助国家:
美国
项目状态:
已结题
起止时间:
2018-07-01 至 2021-06-30

项目摘要

项目成果

Javier Gordon Ogembo的其他基金

相似基金

相关文献

中文摘要
翻译
项目摘要 使用免疫抑制药物来预防移植后的干细胞/器官排斥, 严重的副作用,包括增加机会性感染或病毒重新激活的风险,如 EB病毒(EBV)。EB病毒感染与许多移植后淋巴增生性淋巴结转移有关。 疾病(PTLD)和其他淋巴瘤。各种非标准化、非特异性的治疗方法被用来 治疗EBV+ PTLD病例,如减少免疫抑制或用抗B抗体治疗 细胞抗原CD 20。然而,这些治疗有相当大的局限性,如增加移植的风险, 抗宿主疾病或免疫系统减弱,由于不加选择地靶向B细胞,癌性或 健康.因此,迫切需要一种新的EBV特异性免疫疗法,中和EBV感染 并靶向EBV+细胞以治疗EBV相关的PTLD和其它淋巴瘤。EBV使用多个包膜 糖蛋白(gps)感染宿主细胞,包括主要的免疫显性gp 350和gH/gL复合物 分别促进进入B细胞和上皮细胞。我们对小鼠的临床前研究表明, 用gp 350和gH/gL疫苗免疫的小鼠血清比单独免疫的小鼠血清更好地预防EBV感染。 免疫原此外,抗gp 350(72 A1)和抗gH/gL(E1 D1)的mAb在体外阻断EBV感染。 B细胞和上皮细胞。此外,其他研究人员已经开发了药物和肽(例如,L2P4) 在体外和体内特异性靶向EBV+细胞。为了克服治疗艾滋病所面临的现有挑战, 针对EBV+ PTLDs和其他淋巴瘤,我们建议开发并联合收割机两种治疗方法:(1)抗- gp 350-gH/gL,抗EBV糖蛋白gp 350和gL/gH的人源化双特异性中和抗体 复合物,用作预防EBV感染的预防剂;和(2)抗-CD 19-P4,一种新的抗体, 由与P4肽缀合的抗-CD 19(B细胞抗原)抗体组成的肽缀合物(APC), 治疗EBV+ PTLD和其它淋巴瘤的免疫抑制剂。在圆满完成 我们的长期目标是在临床前试验中测试双特异性nAb和APC的组合使用。 试验作为一种创新的免疫疗法,针对EBV相关的PTLD和淋巴瘤, 免疫功能低下的患者。
英文摘要
PROJECT SUMMARY The use of immunosuppressive drugs to prevent stem cell/organ rejection post-transplant imposes several serious side effects, including increased risk of opportunistic infections or reactivation of viruses such as Epstein-Barr virus (EBV). Infection with EBV is associated with numerous post-transplant lymphoproliferative diseases (PTLDs) and other lymphomas. A variety of non-standardized, non-specific treatments are used to treat EBV+ PTLD cases, such as reduction of immunosuppression or treatment with antibodies against the B cell antigen CD20. However, these treatments have considerable limitations, such as increased risk of graft- versus-host disease or weakened immune system, due to indiscriminate targeting of B cells, cancerous or healthy. Thus, there is an urgent need for a novel EBV-specific immunotherapy that neutralizes EBV infection and targets EBV+ cells to treat EBV-related PTLDs and other lymphomas. EBV uses multiple envelope glycoproteins (gps) to infect host cells, including the major immunodominant gp350 and the gH/gL complex that facilitate entry into B cells and epithelial cells, respectively. Our pre-clinical studies in mice showed that sera from mice immunized with both gp350 and gH/gL vaccines prevented EBV infection better than individual immunogens. Furthermore, mAbs against gp350 (72A1) and anti-gH/gL (E1D1) block in vitro EBV infection of both B cells and epithelial cells. In addition, other researchers have developed drugs and peptides (e.g., L2P4) that specifically target EBV+ cells in vitro and in vivo. To overcome the existing challenges facing treatment of EBV+ PTLDs and other lymphomas, we propose to develop and combine two lines of treatment: (1) anti- gp350-gH/gL, a humanized bispecific neutralizing antibody against EBV glycoproteins gp350 and gL/gH complex for use as a prophylactic agent to prevent EBV infection; and (2) anti-CD19–P4, a novel antibody- peptide conjugate (APC) comprised of anti-CD19 (B cell antigen) antibody conjugated to P4 peptide for use as an immunotherapeutic agent to treat EBV+ PTLDs and other lymphomas. Following the successful completion of this proposal, our long-term goal is to test combinatorial use of the bispecific nAb and APC in pre-clinical trials as an innovative immunotherapeutic treatment against EBV-associated PTLDs and lymphomas for immunocompromised patients.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Unmasking the roles of viral glycoproteins in oral transmission of KSHV
KSHV Subunit Vaccine Candidates to Elicit Potent Humoral Immune Reponses against KSHV Infection
Unmasking the roles of viral glycoproteins in oral transmission of KSHV
Unmasking the roles of viral glycoproteins in oral transmission of KSHV
海外基金